What guidance did Tempus AI's management provide for the next earnings period?

Did Tempus AI beat or miss consensus estimates last quarter?

What were the key takeaways from Tempus AI's earnings call?

What is Tempus AI's latest dividend and current dividend yield?

What were the key takeaways from Tempus AI’s earnings call?

What is the revenue and EPS growth rate for Tempus AI year over year?

What factors drove the changes in Tempus AI's revenue and profit?

What is the market's earnings forecast for Tempus AI next quarter?

- **Revenue Surge**: 33% YoY total revenue growth, 29% Diagnostics unit growth, 69% Data Licensing expansion.
- **MRD Breakthrough**: 56% QoQ MRD growth, 20x scaling potential with full sales force deployment.
- **ASP Target**: $2,200+ by 2026 via FDA approvals and payer rate hikes.
- **Data Dominance**: $1.1B TCV, 126% net retention, 40% Licensing growth driven by unique multimodal data advantage.
- **Foundation Model**: Internal tests show 10+ biomarker improvements, targeting AZ validation.

**【CEO Summary Section】**
- Total revenue grew 33% YoY, driven by Diagnostics (29% unit growth) and Data Licensing (69% Q4 growth). MRD tests increased 56% QoQ, with potential 20x scaling if sales force expands.
- Data business TCV exceeds $1.1B, with 126% net retention. Foundation model for Oncology shows strong performance, targeting AZ benchmarks.
- 2026 guidance includes $1.59B Data revenue and $65M+ EBITDA, supported by 40% growth in Licensing and Applications.

**【CFO Financial Commentary】**
- Q4 ASPs reached $1,640, up $40 QoQ, with $500+ upside by 2026 via FDA approvals (xT CDx, xF liquid biopsy) and payer negotiations.
- 2026 EBITDA guidance of $65M+ reflects cost control and scale benefits. Balance sheet remains strong with no near-term debt maturities.

**【Q&A Key Highlights】**
- **Data Strategy**: Tempus' 450+ petabyte multimodal data set and 5,500+ hospital connections provide unique competitive advantage. Clients re-up contracts due to AI-driven insights for drug development.
- **MRD Expansion**: 4,700 Q4 tests (56% QoQ growth) with <5% sales force allocation. Full sales force enablement could boost volume 20x, pending reimbursement.
- **ASP Drivers**: xT CDx FDA transition (90%+ volume by 2026), xF launch, and commercial payer rate increases. Target ASP of $2,200+ by 2026.
- **Oncology Growth**: 29% Q4 unit growth, 56% MRD growth, and 23% Hereditary growth. Liquid biopsy (xF) outpaces solid tumor (xT) growth.
- **Foundation Model Impact**: Internal tests show model improvements in biomarker accuracy, with external validation underway. Potential to enhance all diagnostic products.


Tempus AI, Inc.(TEM)-20260225-2025 Q4 Earnings call transcript

- **Record Growth**: Oncology (+27%) and Hereditary (+37%) testing volumes driven by efficient sales force and comprehensive portfolio. Data licensing bookings of $150 million highlight strong demand for differentiated analytics.
- **Profitability Milestone**: First-quarter positive EBITDA ($4 million) achieved despite Paige acquisition costs; full-year EBITDA expected to be slightly positive.
- **Strategic Expansion**: Paige acquisition integrates digital pathology with genomics, enabling faster, more accurate diagnostics. Regulatory filings for xF and xR position for long-term reimbursement upside.
- **Sustainable Growth**: 25%+ annual growth target for Genomics and Insights businesses supported by cost control and multiyear data licensing contracts.

**【CEO Summary Section】**
- **Q3 2025 Performance**: Genomics volume grew 3% overall, with Oncology up 27% and Hereditary up 37%. Data licensing bookings reached $150 million, driving Insights business growth of 38%. Achieved first-time positive adjusted EBITDA of $4 million (excluding Paige acquisition costs), with full-year EBITDA expected to be slightly positive.
- **Strategic Initiatives**: MRD reimbursement on track; liquid biopsy xF regulatory filing planned for late 2025. Paige acquisition integrates digital pathology with genomics to enhance diagnostic accuracy and speed.

**【CFO Financial Commentary】**
- **Financial Highlights**: GAAP net income of $420 million; Non-GAAP EPS of $1.08 exceeded expectations. Adjusted EBITDA turned positive due to cost control and operational efficiency. Paige acquisition added $2 million in quarterly expenses but did not impede EBITDA positivity.
- **Guidance**: Full-year adjusted EBITDA expected to be slightly positive, despite Paige-related drag. Reimbursement for xF and xR expected to provide long-term margin upside, with current average reimbursement at $1,600 per test.

**【Q&A Key Highlights】**
- **MRD Testing**: 27% unit growth in Oncology driven by comprehensive portfolio; Paige's tumor-naive assays for CRC and lung cancer expected to yield data in 2026. No plans for aggressive market expansion post-reimbursement.
- **Reimbursement & Pricing**: xF FDA submission in Q4 2025; xR PMA submission to follow. ADLT status for FDA-approved tests could increase Medicare list prices, closing gap with peers.
- **Data Licensing**: $150 million in multiyear bookings reflect differentiated data asset; annual contract value >$350 million. Growth driven by software tools and library licensing.
- **Hereditary Business**: Low double-digit industry growth baseline; Ambry expects low to mid-20s growth, with 50% of Q3 gain from share capture. Rare disease testing ASPs higher but still small-scale.
- **Paige Synergies**: Digital pathology algorithms enhance sequencing by predicting mutations when NGS fails; multimodal approach to patient data expected to scale rapidly with reimbursement.

Tempus AI, Inc. (TEM) Q3 2025 Earnings Call Transcript

- **Revenue Super Growth**: 89.6% YoY to $314.6M, Genomics up 115%, Data & Services +35.7%.
- **EBITDA Turnaround**: Sequential improvement to -$5.6M, on track for $5M breakeven by year-end.
- **AI & Data Expansion**: $750M convertible notes fund growth, 41% Insights revenue surge, $350PB data partnership with AstraZeneca.
- **MRD Catalyst**: End-2025 reimbursement target, rare/pediatric testing at #2 market share.
- **Cash Strong**: $290M liquidity, $375M debt reduction.

**【CEO Summary Section】**
- Q2 2025 revenue surged 89.6% YoY to $314.6 million, driven by Genomics (+115%) and Data & Services (+35.7%).
- Genomics revenue reached $241.8M, with oncology volumes up 26% QoQ and hereditary testing at 32% of total.
- Adjusted EBITDA improved sequentially to -$5.6M, narrowing from -$16M last quarter, with full-year guidance of $5M breakeven.
- Issued $750M 0.75% convertible notes, reducing interest expense and enhancing cash position to $290M.
- Raised 2025 revenue guidance to $1.26B, up from prior $1.1B, with $110M EBITDA improvement YoY.

**【CFO Financial Commentary】**
- Q2 gross profit $195M (+160% YoY), with Data & Services Insights growing 41%.
- Sequential EBITDA improvement reflects disciplined investment in growth drivers like MRD and AI partnerships.
- Cash & marketable securities at $290M, with $375M net debt reduction post-convertible notes issuance.

**【Q&A Key Highlights】**
- **Genomics Growth**: Oncology volumes up 28% QoQ, hereditary testing outperforming expectations, rare/pediatric testing at #2 market share.
- **Data Business**: Signed $350PB clinical data partnership with AstraZeneca, Insights revenue up 41%.
- **MRD Reimbursement**: Targeting end-2025 MolDx approval, with potential 2026 revenue impact.
- **AI Strategy**: Building foundation models for drug discovery, with 1,000 H200 GPUs and 350PB data integration.
- **Liquidity**: $290M cash, $750M convertible notes reducing interest expense by ~$30M annually.

Tempus AI, Inc. (TEM) Q2 2025 Earnings Call Transcript

- **Record Q1 Growth**: $255.7M revenue (+75.4% YoY), $155.2M gross profit (+99.8% YoY). Full-year 2025 guidance raised to $1.25B.
- **Breakthrough Deal**: $200M AZ-Pathos partnership adds 300+ PB data, pushing total RCV >$1B. First model version expected in 9-12 months.
- **Data Business Strength**: 43% YoY growth in Data & Services. $940M pre-signed contracts at Q1 start, now >$1B RCV.
- **Cost Efficiency**: 5% YoY opex decline. Adjusted EBITDA improved $27.8M YoY to -$16.2M.
- **MRD Pipeline**: xM assay volumes controlled due to no reimbursement. Personalis tumor-informed assay shows 99.7% sensitivity.


**【CEO Opening Remarks】**
- Q1 2025 revenue reached $255.7 million, up 75.4% YoY, driven by 89% growth in genomics revenue ($193.8M) and 31% growth in oncology testing. Data & Services segment grew 43% YoY to $61.9 million.
- Gross profit surged 99.8% YoY to $155.2 million, with adjusted EBITDA improving to -$16.2 million (vs. -$43.9M YoY). Full-year 2025 revenue guidance raised to $1.25 billion (+80% YoY).
- Announced $200M 3-year data licensing deal with AstraZeneca & Pathos, adding 300+ petabytes of multimodal data. Total remaining contract value exceeds $1 billion.

**【CFO Financial Highlights】**
- GAAP net income: $42.1 million. Non-GAAP EPS: $1.08 (vs. $0.85 consensus). Adjusted EBITDA improved $27.8 million YoY.
- Data licensing revenue from AZ-Pathos deal will be recognized ratably over 3 years. First-year contribution: ~$67 million. Remaining contract value: $1.03 billion.
- Cost control achieved 5% YoY decline in operating expenses, driving 20%+ operating margin expansion.

**【Key Q&A Takeaways】**
- **AZ-Pathos Deal Structure**: $50M upfront payment, $35M compute cost reimbursement, $150M variable consideration (50% stock). No upfront revenue recognition; 3-year subscription model.
- **Hereditary Testing Growth**: 23% unit growth vs. prior guidance of mid-teens. Driven by unmet demand in inherited disease risk assessment.
- **MRD Pipeline Momentum**: xM assay volumes metered due to lack of reimbursement. Tumor-informed assay (Personalis) shows 99.7% sensitivity; tumor-naive assay in colorectal cancer performs well in early studies.
- **Data Business Visibility**: $940M of signed but undelivered contracts at Q1 start. AZ deal adds $200M+ pipeline visibility.

**【Long-Term Investment Priorities】**
- Genomics expansion: MRD, tumor-naive platforms, liquid biopsy innovation.
- AI & foundation models: Compute infrastructure, multimodal data integration, clinical trial optimization.
- Strategic partnerships: Pharma collaborations, clinical trial data sharing networks.


Tempus AI (TEM)-6 May 25-2025 Q1 Earnings call transcript

- **Revenue Acceleration**: Q4 2024 saw 35.8% YoY growth, driven by genomics and data businesses. Gross profit surged 49.7%.
- **Ambry Synergy**: 2025 Ambry contribution expected at 17-19% YoY, with West Coast lab integration to enhance redundancy.
- **Data Contract Strength**: $940 million total remaining contract value ensures 2025 visibility, with 140% net retention.
- **AI Expansion**: Launch of Olivia AI app and integration of third-party algorithms into Tempus network highlight AI-driven growth.
- **Profit Milestone**: 2025 guidance includes $5 million adjusted EBITDA, marking cash flow positivity.

**【CEO Summary Section】**
- **Revenue Growth**: Q4 2024 revenue grew 35.8% YoY, with gross profit up 49.7%. Total remaining contract value reached $940 million, and net revenue retention hit 140%.
- **Acquisition Update**: Closed the Ambry Genetics acquisition on February 3, integrating a West Coast lab to enhance redundancy and workflow expansion.
- **Guidance Update**: Raised 2025 revenue guidance to $1.24 billion and expects $5 million of adjusted EBITDA, driven by accelerating growth in genomics and data businesses.
- **AI and Data Strategy**: Highlighted the success of the Data and Services business, with plans to integrate AI applications like Olivia AI into patient care.

**【CFO Financial Commentary】**
- **Financial Performance**: Q4 2024 GAAP net income was $420 million, with Non-GAAP EPS exceeding expectations at $1.08. Strong cost control reduced operating expenses by 5% YoY.
- **Seasonality and Contribution**: Ambry contributed 2 months of results in Q1 2025, with expected gradual ramp-up. Seasonality similar to core Tempus business, with Q1 typically the lowest revenue quarter.
- **Contract Visibility**: $940 million total remaining contract value provides visibility into 2025, with large agreements driving predictable revenue streams.

**【Q&A Key Highlights】**
- **Ambry Integration**: Ambry's West Coast lab will enable somatic workflow expansion over 1-2 years. 2025 growth rate for Ambry estimated at 17-19%, lower than 2024 due to lapped accelerants.
- **Data Business Dynamics**: Lumpy growth in data contracts (e.g., $10 million delayed delivery) impacts quarterly revenue. Long-term visibility from $940 million contract backlog, with 140% net retention.
- **Reimbursement Wins**: Secured ADLT status for 20% of XT volume in Q1, with Medicare reimbursement uplift for liquid biopsy. New in-network Blue Cross/Blue Shield partnerships to improve commercial payer ASPs.
- **AI and Regulatory Tailwinds**: FDA regulatory changes viewed as tailwinds for AI diagnostics. Launch of Olivia AI app for personalized health insights, monetized via $12/month subscription.
- **Capital Allocation**: No major M&A planned; focus on small data/AI acquisitions. 2025 investments balanced between growth and EBITDA positivity, with no immediate profit maximization.

Actual	-0.63	-0.25	-0.18	-0.24	-0.22	-0.11	-0.04
Forecast	-3.5467	-0.2661	-0.1563	-0.26	-0.2299	-0.1723	-0.0414
Surprise	+82.24%	+6.05%	-15.16%	+7.69%	+4.31%	+36.16%	+3.38%

Actual	165.97M	180.93M	200.68M	255.74M	314.63M	334.21M	367.21M
Forecast	160.30M	179.52M	203.12M	248.13M	297.74M	328.70M	362.75M
Surprise	+3.54%	+0.78%	-1.20%	+3.07%	+5.67%	+1.67%	+1.23%

TEM

TEM fundamentals

TEM Q4 2025 Earnings

Earnings Call

You can ask Aime

TEM

TEM fundamentals

TEM Q4 2025 Earnings

Earnings Call

TEM Earnings Call Summary for Q4/20254:30 PM on Feb 24, 2026

TEM Earnings Call Summary for Q3/20254:30 PM on Nov 4, 2025

TEM Earnings Call Summary for Q2/20258:00 AM on Aug 8, 2025

TEM Earnings Call Summary for Q1/20254:30 PM on May 6, 2025

TEM Earnings Call Summary for Q4/20244:30 PM on Feb 24, 2025

You can ask Aime